What are the latest FDA‑approved updates for the treatment of limited‑stage (LS) and extensive‑stage (ES) small cell lung cancer (SCLC)?

Latest Updates in Small Cell Lung Cancer Treatment

The most significant recent update is the FDA approval of tarlatamab, a novel bispecific T-cell engager, for relapsed SCLC, which joins topotecan and lurbinectedin as preferred second-line agents, while durvalumab consolidation after chemoradiotherapy is now strongly recommended for limited-stage disease. 1

Limited-Stage SCLC (LS-SCLC)

Consolidation Immunotherapy - Major Update

Patients with LS-SCLC who complete concurrent chemoradiotherapy without disease progression should receive durvalumab consolidation for up to 2 years. 1 This represents a paradigm shift in LS-SCLC management, extending the immunotherapy approach that has proven successful in extensive-stage disease to the limited-stage setting.

• Even patients with poor performance status (ECOG PS 3-4) may be offered durvalumab consolidation if their performance status improves after chemoradiotherapy, though this carries a conditional recommendation due to lower quality evidence. 1

Extensive-Stage SCLC (ES-SCLC)

First-Line Treatment Standard

Platinum-etoposide chemotherapy combined with either atezolizumab or durvalumab for 4 cycles, followed by maintenance immunotherapy, remains the standard first-line treatment. 1

• Atezolizumab plus carboplatin-etoposide demonstrated improved overall survival (OS) with median OS of 12.3 months versus 10.3 months for chemotherapy alone (HR 0.70, p=0.007). 1, 2
• Durvalumab plus platinum-etoposide showed median OS of 13.0 months versus 10.3 months with chemotherapy alone (HR 0.73, p=0.005). 1, 2
• The 1-year OS rates improved from 38-40% with chemotherapy alone to 52-54% with chemoimmunotherapy. 1

Second-Line Treatment - Breakthrough Update

Tarlatamab is the newest FDA-approved agent for relapsed SCLC and demonstrates superior duration of response compared to other available options. 1

Tarlatamab Specifics

• Overall response rate of 40% with a remarkable median duration of response of 9.7 months, substantially longer than other second-line agents. 1
• Particularly effective in platinum-resistant disease (52% response rate) compared to platinum-sensitive disease (31% response rate). 1
• Median progression-free survival of 4.9 months with 9-month PFS and OS rates of 28% and 68%, respectively. 1

Dosing and Administration

The recommended regimen is 1 mg IV on day 1 of cycle 1, followed by 10 mg on days 8 and 15 of cycle 1, then 10 mg every 2 weeks thereafter. 1

• Critical safety requirement: 24-hour inpatient monitoring after the first two doses (days 1 and 8 of cycle 1) due to cytokine release syndrome (CRS) risk. 1
• CRS occurred in 51% of patients but was predominantly grade 1-2 (30% grade 1,20% grade 2, only 1% grade 3), with median onset at 13 hours and duration of 4 days. 1
• Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in only 8% of patients, all grade 1-2. 1
• Grade ≥3 treatment-related adverse events occurred in 26% of patients, but severe CRS and ICANS were rare (1% and 0%, respectively). 1

Second-Line Treatment Algorithm

For chemotherapy-free interval <90 days (platinum-resistant):

• Preferred single agents: tarlatamab, lurbinectedin, or topotecan. 1
• Single-agent therapy is preferred over multiagent regimens due to better risk-benefit balance. 1

For chemotherapy-free interval ≥90 days (platinum-sensitive):

• Either rechallenge with platinum-based regimen OR single-agent therapy with tarlatamab, lurbinectedin, or topotecan. 1

Sequencing Considerations

There are currently no head-to-head trials comparing tarlatamab, lurbinectedin, and topotecan, making optimal sequencing unclear. 1 Cross-trial comparisons suggest both tarlatamab and lurbinectedin are more effective than topotecan, but tarlatamab's >9-month duration of response is substantially longer than other agents. 1 The ongoing DeLLphi-304 trial comparing tarlatamab with standard chemotherapy will provide definitive guidance. 1

Key Clinical Pitfalls

• Do not use tarlatamab in patients with prior severe immune-related adverse events, grade ≥2 pneumonitis from previous immunotherapy, or active CNS metastases requiring urgent intervention. 1
• Patients who received first-line immunotherapy (now standard) may have different responses to second-line agents, as most historical trial data enrolled immunotherapy-naive patients. 3, 4
• Subset analyses suggest patients with brain metastases may not benefit from first-line immunotherapy, and those younger than 65 derive greater benefit. 1

Supportive Care Update

Trilaciclib, a CDK 4/6 inhibitor, is FDA-approved for administration prior to platinum-etoposide or topotecan-containing regimens to reduce chemotherapy-induced myelosuppression. 4, 5